Skip to content
Screener

Novavax NVAX Business Segments — Employee and benefit expenses

Similar metrics at other companies

Rollins logo
ROLReportable Segment — Employee expenses
$328.79M+10.2%
Lowe's Companies logo
LOWReportable Segment — Employee compensation and benefits
13.4%-0.1pp
Fulton Financial logo
FULTReportable Segment — Salaries and employee benefits
$110.89M+2.5%
LPR
LPROReportable Segment — Employee compensation and benefits
$9.04M-13.7%
BGC Group, Inc. logo
BGCReportable Segment — Compensation and employee benefits
$537.34M+57.3%
Rimini Street, Inc. logo
RMNIReportable Segment — Employee compensation and benefits
$25.41M+1.5%

Other financials

Income statement

See full
Revenue$56.7M-76.3%
Gross profit$42.5M-81.0%
Operating income-$54.9M-154%
Net income-$53.4M-150%
EPS (diluted)-$0.32-152%

Balance sheet

See full
Cash & equivalents$191.5M-24.5%
Total debt$297.3M+413%
Total equity-$190.7M-607%
Total assets$955.6M-28.5%

Cash flow

See full
Operating cash flow-$72.8M+42.9%
CapEx$588.0K+11.6%
Free cash flow-$73.4M+42.7%

Valuation

See full
Market cap$1.27B+3.7%
Enterprise value$1.38B+33.6%
P/S3.1×+1.9×

Profitability

See full
Gross margin78.6%-9.6pp
Operating margin-56.6%-89.2pp
Net margin-59.9%-99.1pp
FCF margin-59%-61.5pp

Returns & leverage

See full
Return on equity-238.6%
Debt / equity1.5×
Current ratio2.3×0.0×

Where this comes from

Reported directly by Novavax in its filing.

Tagged under the XBRL concept nvax:ResearchAndDevelopmentExpenseEmployeeAndBenefitExpenses.

The source filing: Novavax’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:50 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001000694-26-000018
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Direct COVID-19 Vaccine(1)20,07313,07754,32828,824
Direct CIC and influenza vaccines7037,1173,55619,621
Direct other vaccine development programs(1)3,1298425,393997
Employee and benefit expenses30,82036,14968,87576,060
Facility and other research and development expenses(2)15,96822,04834,01342,668
Selling, general, and administrative expense26,66543,61255,44291,702
Other segment income (expense)(3)1,5195,4387,4588,570
Net income (loss)$(53,387)$106,508$(62,878)$625,154

Item 1. Consolidated Financial Statements

FAQ

What is Novavax's business segments — employee and benefit expenses?
Novavax (NVAX) reported business segments — employee and benefit expenses of $30.82M in Q2 2026.
What does business segments — employee and benefit expenses mean?
This metric captures the total costs incurred for personnel, including salaries, bonuses, stock-based compensation, and associated benefits. It serves as a primary indicator of the company's investment in human capital required to drive research, development, and commercialization efforts. Analyzing this expense provides insight into the company's operational scale and its ability to attract and retain the specialized talent necessary for biotechnology innovation.

Ask your AI about Novavax's business segments — employee and benefit expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude